Zealand Pharma

Copenhagen, 2015-04-06 21:49 CEST (GLOBE NEWSWIRE) -- 6 April 2015 ? Pursuant
to the Danish Securities Trading Act, section 28a, Zealand Pharma (“Zealand”)
(Nasdaq Copenhagen: ZEAL) must disclose information on transactions with the
company’s shares and related securities by executives and persons/companies
closely related to them.

With reference to the above, Zealand announces it has received information on
the following transaction for disclosure:

Name: Alain Munoz

Reason: Member of the Board of Directors

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Sale of shares

Trading Date: 27 March 2015

Market: Nasdaq Copenhagen

Number: 1,750

Price: DKK 105.06 (EUR 14.06)

Market value: DKK 183,850.02 (EUR 24,609.02)

                                  ?????

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel: +45 51 67 61 28, email: [email protected]

Hanne Leth Hillman, Senior Vice President for Communications and Investor
Relations

Tel: +45 50 60 36 89, email: [email protected]

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a pipeline of novel wholly-owned medicines alongside a partnered
product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory
submissions for LixiLan in Q4 2015.

Zealand’s wholly-owned products include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207
(treatment of severe hypoglycemia) in Phase I as well as several preclinical
peptide therapeutics. Partnering represents an important component of strategy
to leverage in-house expertise, share development risk in large clinical
trials, provide funding and commercialize the company’s products. Zealand
currently has global license agreements and partnerships with Sanofi, Helsinn
Healthcare, Boehringer Ingelheim and Eli Lilly.

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma

AI Terminal